Vera Therapeutics, Inc. (NASDAQ:VERA) Holdings Raised by Deutsche Bank AG

Deutsche Bank AG raised its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 5.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 810,376 shares of the company’s stock after buying an additional 43,832 shares during the period. Deutsche Bank AG owned approximately 1.28% of Vera Therapeutics worth $34,271,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new position in shares of Vera Therapeutics during the 4th quarter valued at about $431,000. Crestline Management LP boosted its holdings in Vera Therapeutics by 97.2% during the fourth quarter. Crestline Management LP now owns 160,347 shares of the company’s stock worth $6,781,000 after buying an additional 79,032 shares in the last quarter. Cutter Capital Management LP grew its position in Vera Therapeutics by 23.0% in the fourth quarter. Cutter Capital Management LP now owns 212,696 shares of the company’s stock worth $8,995,000 after buying an additional 39,820 shares during the last quarter. Balyasny Asset Management L.P. increased its holdings in shares of Vera Therapeutics by 119.5% in the fourth quarter. Balyasny Asset Management L.P. now owns 385,425 shares of the company’s stock valued at $16,300,000 after buying an additional 209,834 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Vera Therapeutics during the 4th quarter valued at $1,031,000. 99.21% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

VERA has been the topic of a number of research analyst reports. HC Wainwright assumed coverage on Vera Therapeutics in a report on Monday, May 5th. They set a “buy” rating and a $75.00 price target on the stock. Guggenheim lifted their price objective on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Wolfe Research initiated coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $49.00 target price for the company. JPMorgan Chase & Co. lowered their price target on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 4th. Finally, The Goldman Sachs Group started coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They issued a “buy” rating and a $58.00 price objective on the stock. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $63.33.

Vera Therapeutics Stock Performance

NASDAQ:VERA opened at $21.58 on Wednesday. Vera Therapeutics, Inc. has a 52-week low of $18.53 and a 52-week high of $51.61. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -8.27 and a beta of 1.28. The firm’s 50-day moving average is $23.92 and its 200-day moving average is $34.43. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). During the same quarter in the prior year, the business earned ($0.56) earnings per share. Equities research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.